REBECCA BEYER: Open Payments
NPI 1528585304 · STUART, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,558 in 105 payments from 21 companies in 2025. Trend: 2023 $3,006 · 2024 $1,369 · 2025 $2,558
Food & beverage: $2,558
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 20 | $439 |
| United Therapeutics Corporation | 8 | $352 |
| GlaxoSmithKline, LLC. | 15 | $259 |
| Actelion Pharmaceuticals US, Inc. | 8 | $233 |
| Verona Pharma, Inc. | 8 | $200 |
| Regeneron Healthcare Solutions, Inc. | 6 | $171 |
| Amgen Inc. | 1 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $113 |
| Merck Sharp & Dohme LLC | 5 | $108 |
| Electromed, Inc. | 10 | $104 |
Products named: TEZSPIRE, Tyvaso, Ohtuvayre, DUPIXENT, FASENRA, TRELEGY ELLIPTA, GLASSIA, WINREVAIR.
Industry payments across FL — which companies pay providers there.
